Oncolytics Biotech (TSE:ONC) Stock Price Passes Above Two Hundred Day Moving Average – Here’s Why

Oncolytics Biotech Inc. (TSE:ONC) shares crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of C$14.90 and traded as high as C$14.90. Oncolytics Biotech shares last traded at C$14.90, with a volume of 280 shares.

Oncolytics Biotech Price Performance

The stock has a 50 day moving average of C$14.90 and a two-hundred day moving average of C$14.90. The company has a debt-to-equity ratio of 14.58, a quick ratio of 8.86 and a current ratio of 2.88. The firm has a market capitalization of C$1.50 billion, a P/E ratio of -40.27 and a beta of 0.80.

Insider Activity at Oncolytics Biotech

In other news, Director Bernd Robert Seizinger acquired 60,000 shares of Oncolytics Biotech stock in a transaction dated Wednesday, February 11th. The stock was acquired at an average cost of C$1.14 per share, for a total transaction of C$68,400.00. Following the completion of the purchase, the director owned 526,991 shares of the company’s stock, valued at C$600,769.74. This represents a 12.85% increase in their ownership of the stock. Also, insider Jared Ryan Kelly acquired 29,500 shares of the firm’s stock in a transaction that occurred on Thursday, February 12th. The shares were purchased at an average cost of C$1.16 per share, with a total value of C$34,220.00. Following the completion of the acquisition, the insider owned 109,000 shares in the company, valued at C$126,440. This trade represents a 37.11% increase in their position. Over the last 90 days, insiders have acquired 289,232 shares of company stock valued at $335,760. 3.82% of the stock is owned by company insiders.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.